AU2021241886A1 - Triazolone compounds - Google Patents
Triazolone compounds Download PDFInfo
- Publication number
- AU2021241886A1 AU2021241886A1 AU2021241886A AU2021241886A AU2021241886A1 AU 2021241886 A1 AU2021241886 A1 AU 2021241886A1 AU 2021241886 A AU2021241886 A AU 2021241886A AU 2021241886 A AU2021241886 A AU 2021241886A AU 2021241886 A1 AU2021241886 A1 AU 2021241886A1
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- pyrimidin
- triazolo
- amino
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994954P | 2020-03-26 | 2020-03-26 | |
| US62/994,954 | 2020-03-26 | ||
| PCT/EP2021/057808 WO2021191380A1 (en) | 2020-03-26 | 2021-03-25 | Triazolone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021241886A1 true AU2021241886A1 (en) | 2022-10-27 |
Family
ID=75302568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021241886A Pending AU2021241886A1 (en) | 2020-03-26 | 2021-03-25 | Triazolone compounds |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12552799B2 (https=) |
| EP (1) | EP4126871B1 (https=) |
| JP (1) | JP7709454B2 (https=) |
| KR (1) | KR20230049580A (https=) |
| CN (1) | CN115867550B (https=) |
| AU (1) | AU2021241886A1 (https=) |
| CA (1) | CA3177057A1 (https=) |
| WO (1) | WO2021191380A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| ATE457988T1 (de) | 2006-06-26 | 2010-03-15 | Schering Corp | A2a-adenosin-rezeptor-antagonisten |
| JP2011513417A (ja) * | 2008-03-04 | 2011-04-28 | シェーリング コーポレイション | アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物 |
| AU2011306358B2 (en) | 2010-09-24 | 2014-08-14 | Impetis Biosciences Ltd. | Fused tricyclic compounds as adenosine receptor antagonist |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| AU2018233367B2 (en) | 2017-03-16 | 2021-08-12 | Jiangsu Hengrui Medicine Co., Ltd. | Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof |
| PL3611174T3 (pl) * | 2017-04-07 | 2022-08-08 | Medshine Discovery Inc. | Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a |
| EP3774813A4 (en) * | 2018-04-08 | 2021-11-17 | BeiGene, Ltd. | PYRAZOLOTRIAZOLOPYRIMIDE DERIVATIVES AS A2A RECEPTOR ANTAGONIST |
| WO2020010197A1 (en) * | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
-
2021
- 2021-03-25 KR KR1020227037225A patent/KR20230049580A/ko active Pending
- 2021-03-25 CN CN202180038087.XA patent/CN115867550B/zh active Active
- 2021-03-25 AU AU2021241886A patent/AU2021241886A1/en active Pending
- 2021-03-25 US US17/914,157 patent/US12552799B2/en active Active
- 2021-03-25 WO PCT/EP2021/057808 patent/WO2021191380A1/en not_active Ceased
- 2021-03-25 JP JP2022558348A patent/JP7709454B2/ja active Active
- 2021-03-25 EP EP21715554.8A patent/EP4126871B1/en active Active
- 2021-03-25 CA CA3177057A patent/CA3177057A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023519363A (ja) | 2023-05-10 |
| JP7709454B2 (ja) | 2025-07-16 |
| KR20230049580A (ko) | 2023-04-13 |
| EP4126871B1 (en) | 2024-05-08 |
| US20230146796A1 (en) | 2023-05-11 |
| WO2021191380A1 (en) | 2021-09-30 |
| US12552799B2 (en) | 2026-02-17 |
| EP4126871A1 (en) | 2023-02-08 |
| CN115867550B (zh) | 2025-01-03 |
| CN115867550A (zh) | 2023-03-28 |
| CA3177057A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4417607A1 (en) | Heterocyclic compound as sos1 inhibitor and uses thereof | |
| JP6159028B2 (ja) | Ｓｙｋ阻害剤 | |
| EP2435438A1 (en) | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use | |
| US20120309739A1 (en) | Akt / pkb inhibitors | |
| EP2451811A1 (en) | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use | |
| JPH03148279A (ja) | アンギオテンシン２拮抗体としての置換イミダゾ融合５員環複素環式化合物 | |
| WO2009053715A1 (en) | Thienopyrimidiene derivatives as pi3k inhibitors | |
| JP2005538118A (ja) | Ｔｉｅ２（ｔｅｋ）活性を持つ縮合したピリジン及びピリミジン | |
| CN115867282B (zh) | 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物 | |
| AU2021241886A1 (en) | Triazolone compounds | |
| WO2021156439A1 (en) | Triazole compounds as adenosine receptor antagonists | |
| CN115867280B (zh) | 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物 | |
| WO2021191376A1 (en) | Triazolone compounds | |
| CN115433211A (zh) | 吡嗪并吡啶酮类蛋氨酸腺苷转移酶2a抑制剂 | |
| HK40088927A (en) | Triazolone compounds | |
| HK40088927B (en) | Triazolone compounds | |
| TW202610638A (zh) | 包含維爾納症候群解旋酶抑制劑之組成物及其使用方法 | |
| EA046747B1 (ru) | Имидазопиримидины и триазолопиримидины в качестве ингибиторов a2а/a2b | |
| HK1224672A1 (en) | Syk inhibitors | |
| HK1224672B (en) | Syk inhibitors |